SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Onesource Specialty Pharma informs about outcome of board meeting

13 May 2026 Evaluate
Onesource Specialty Pharma has informed that Board of Directors of the Company, in their meeting held today i.e., on Wednesday, May 13, 2026, have approved the following: 1. Audited Financial Results (Standalone and Consolidated) of the Company for quarter and year ended March 31, 2026. In this regard, it has enclosed: (i) A copy of the Audited Financial Results (Standalone and Consolidated) for quarter and year ended March 31, 2026, along with Auditors’ Report; and (ii) Declaration of unmodified opinion in the Auditors’ Report for the financial year ended March 31, 2026 enclosed herewith as Annexure A; Appointment of B S R & Co LLP, Chartered Accountants (Firm’s Registration No.:101248W/W-100022), as the statutory auditors of the Company to hold office from the conclusion of the 19th Annual General Meeting for a term of five consecutive years, i.e., until the conclusion of the 24th Annual General Meeting, in place of Deloitte Haskins & Sells, Chartered Accountants (Firm Registration No. 008072S), whose term is ending on the ensuing annual general meeting. Disclosure pursuant to Regulation 30 of the SEBI Listing Regulations., read with SEBI Master Circular No. O/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026, enclosed as Annexure B.

The above information is a part of company’s filings submitted to BSE.

Onesource Specialty Share Price

1613.40 -35.80 (-2.17%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: